All
Frontline Nivolumab Improves OS, PFS Versus Dacarbazine in Advanced Melanoma
November 19th 2014Frontline treatment with nivolumab (Opdivo) significantly extended overall survival (OS) and progression-free survival (PFS) when compared with dacarbazine in patients with untreated BRAF wild-type advanced melanoma.
The Management of Treatment-Related AEs in Advanced CRC
November 12th 2014As new therapies enter the treatment landscape for metastatic disease, the role of the oncology nurse becomes even more critical in educating patients about what side effects to look out for and the importance of reporting any adverse events promptly.
Access to Radium-223 Restored Following Brief Suspension
November 7th 2014Bayer HealthCare Pharmaceuticals restored access to radium-223 dichloride (Xofigo) following a temporary suspension in production to adjust its manufacturing process to meet certain quality standards that the company has in place.
ODAC Votes 5-2 Against Panobinostat in Myeloma
November 7th 2014The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 5-2 against the accelerated approval of panobinostat (Farydak) in combination with bortezomib (Velcade) and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Ramucirumab Plus Paclitaxel Gains Approval for Advanced Gastric Cancer
November 7th 2014Based on data from the phase III RAINBOW trial, the FDA has approved ramucirumab (Cyramza) in combination with paclitaxel as a treatment for patients with previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Trebananib Does Not Improve Survival in Ovarian Cancer
November 5th 2014A statistically significant improvement in overall survival (OS) was not seen with the combination of paclitaxel and the angiogenesis inhibitor trebananib when compared with paclitaxel alone for patients with recurrent platinum-resistant ovarian cancer.
Serum Metabolite Concentrations May Prove Useful for Lung Cancer Detection
October 28th 2014Early diagnosis of lung cancer is crucial, because surgery is curative only in the early stages. However, by the time most patients experience symptoms, the cancer has already progressed beyond the point of successful surgery.
Pembrolizumab Granted Breakthrough Therapy Designation in NSCLC
October 27th 2014The FDA has granted a breakthrough therapy designation to pembrolizumab for the treatment of patients with NSCLC who are EGFR mutation- or ALK rearrangement-negative and whose disease has progressed on or following platinum-based chemotherapy.
TAS-102 Receives Fast Track Designation for mCRC
October 21st 2014TAS-102 (tipiracil hydrochloride) has received a fast track designation from the FDA as a treatment for patients with refractory metastatic colorectal cancer (mCRC), according to an announcement by Taiho Oncology, the company developing the drug in the US.
Priority Review Granted to Lenvatinib for RAI-Refractory DTC
October 18th 2014The FDA has granted a priority review to the oral multiple tyrosine kinase receptor inhibitor lenvatinib as a treatment for patients with progressive, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC).
Novel Combination May Extend Survival in Ovarian Cancer
October 17th 2014Two agents with contrasting mechanisms of actions exert synergistic effects while limiting tumor blood supply in ovarian cancer. Patient enrollment began this month (October 2014) for a new phase 1b/2 clinical study1 to evaluate this novel combination with the VDA fosbretabulin plus pazopanib.
Bayer Suspends Production of Radium-223 Due to Manufacturing Problem
October 16th 2014Production of the prostate cancer drug radium-223 (Xofigo) has been suspended indefinitely by its maker, Bayer HealthCare Pharmaceuticals, due to a manufacturing problem. The company confirmed the manufacturing suspension in a statement released to Targeted Oncology.